Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ADXS NASDAQ:ATHE NASDAQ:GRML OTCMKTS:LTUS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADXSAyala Pharmaceuticals$0.60$0.60$0.00▼$0.80$35.79M1.7515,632 shsN/AATHEAlterity Therapeutics$4.20-98.0%$4.20$4.00▼$350.00$37.13M0.3623 shs431 shsGRMLGreenland Mines Ltd. Common Stock$0.30-1.6%$0.44$0.21▼$2.02$36.37M6.943.41 million shs39,850 shsLTUSLotus Pharmaceuticals$0.00$0.00$0.00▼$0.01$9.52M-1.682,465 shsN/A7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADXSAyala Pharmaceuticals0.00%0.00%0.00%0.00%+1,701.64%ATHEAlterity Therapeutics-0.96%+4.58%-14.91%+14.17%-12.55%GRMLGreenland Mines Ltd. Common Stock+4.10%-8.96%-27.38%-41.82%-78.97%LTUSLotus Pharmaceuticals0.00%0.00%0.00%-11.40%-50.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADXSAyala Pharmaceuticals$0.60$0.60$0.00▼$0.80$35.79M1.7515,632 shsN/AATHEAlterity Therapeutics$4.20-98.0%$4.20$4.00▼$350.00$37.13M0.3623 shs431 shsGRMLGreenland Mines Ltd. Common Stock$0.30-1.6%$0.44$0.21▼$2.02$36.37M6.943.41 million shs39,850 shsLTUSLotus Pharmaceuticals$0.00$0.00$0.00▼$0.01$9.52M-1.682,465 shsN/A7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADXSAyala Pharmaceuticals0.00%0.00%0.00%0.00%+1,701.64%ATHEAlterity Therapeutics-0.96%+4.58%-14.91%+14.17%-12.55%GRMLGreenland Mines Ltd. Common Stock+4.10%-8.96%-27.38%-41.82%-78.97%LTUSLotus Pharmaceuticals0.00%0.00%0.00%-11.40%-50.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADXSAyala Pharmaceuticals 0.00N/AN/AN/AATHEAlterity Therapeutics 2.00HoldN/AN/AGRMLGreenland Mines Ltd. Common Stock 1.00SellN/AN/ALTUSLotus Pharmaceuticals 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest LTUS, GRML, ATHE, and ADXS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/9/2026GRMLGreenland Mines Ltd. Common Stock Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)4/22/2026GRMLGreenland Mines Ltd. Common Stock Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/20/2026ATHEAlterity Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)(Data available from 6/12/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADXSAyala Pharmaceuticals$3.24M11.05N/AN/A($2.06) per share-0.29ATHEAlterity TherapeuticsN/AN/AN/AN/A$3.10 per shareN/AGRMLGreenland Mines Ltd. Common StockN/AN/AN/AN/A$0.13 per shareN/ALTUSLotus PharmaceuticalsN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADXSAyala Pharmaceuticals-$48.07M-$5.02N/AN/AN/AN/AN/AN/AN/AATHEAlterity Therapeutics-$7.87MN/AN/AN/AN/AN/AN/AN/A8/28/2026 (Estimated)GRMLGreenland Mines Ltd. Common Stock-$10.55M-$0.32N/AN/AN/AN/A-109.40%-98.80%N/ALTUSLotus Pharmaceuticals-$30KN/AN/AN/AN/AN/AN/AN/AN/ALatest LTUS, GRML, ATHE, and ADXS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/20/2026Q1 2026GRMLGreenland Mines Ltd. Common StockN/A-$0.15N/A-$0.15N/AN/A4/1/2026Q4 2025GRMLGreenland Mines Ltd. Common StockN/A$0.01N/A$0.01N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthADXSAyala PharmaceuticalsN/AN/AN/AN/AN/AATHEAlterity TherapeuticsN/AN/AN/AN/AN/AGRMLGreenland Mines Ltd. Common StockN/AN/AN/AN/AN/ALTUSLotus PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADXSAyala PharmaceuticalsN/AN/AN/AATHEAlterity TherapeuticsN/A21.97N/AGRMLGreenland Mines Ltd. Common StockN/A19.7319.73LTUSLotus PharmaceuticalsN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADXSAyala Pharmaceuticals7.18%ATHEAlterity Therapeutics2.14%GRMLGreenland Mines Ltd. Common Stock20.07%LTUSLotus PharmaceuticalsN/AInsider OwnershipCompanyInsider OwnershipADXSAyala Pharmaceuticals0.63%ATHEAlterity Therapeutics38.80%GRMLGreenland Mines Ltd. Common Stock11.30%LTUSLotus PharmaceuticalsN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableADXSAyala Pharmaceuticals2059.31 million42.36 millionNot OptionableATHEAlterity Therapeutics108.87 million5.43 millionNot OptionableGRMLGreenland Mines Ltd. Common Stock5121.24 million107.54 millionN/ALTUSLotus Pharmaceuticals2302.64 billionN/ANot OptionableLTUS, GRML, ATHE, and ADXS HeadlinesRecent News About These CompaniesLotus Pharmaceuticals Inc.March 31, 2026 | barrons.comLotus Pharma partners with Formycon on biosimilar of KeytrudaFebruary 11, 2026 | thepharmaletter.comTGlenmark Specialty S.A. and Lotus International Pte. Ltd. enter into exclusive licensing agreement for commercializing Ryaltris™ Nasal Spray in Singapore, Hong Kong and VietnamJanuary 15, 2026 | aninews.inAInnobic buys Alvogen PharmaDecember 7, 2025 | bangkokpost.comBLENZ Therapeutics Announces MFDS Submission of New Drug Application for LNZ100 (VIZZ™) in South ...December 1, 2025 | caledonianrecord.comCBoryung Acquires Taxotere Global Business to Expand into 19 CountriesOctober 29, 2025 | msn.comAvalo Therapeutics completes enrollment in Phase 2 LOTUS trialOctober 29, 2025 | msn.comAvalo Therapeutics Announces Completion of Enrollment in Phase 2 LOTUS Trial of AVTX-009 for ...October 29, 2025 | caledonianrecord.comCRx Rundown: Genmab, Novartis, AstraZeneca and moreOctober 2, 2025 | mmm-online.comMAlvogen Pharma announces sale to Lotus Pharmaceutical, creating a leading global specialized generics platformSeptember 25, 2025 | pharmabiz.comPAlvogen Announces Sale to Lotus, Creating a Leading International Specialized Generics PlatformSeptember 23, 2025 | finance.yahoo.comTwin Lotus: 52 Years of Herbal Innovation Goes GlobalSeptember 22, 2025 | khaosodenglish.comKPhase IV Trial Shows Daybue Demonstrates Real-World Behavioral Improvements in Rett SyndromeSeptember 15, 2025 | appliedclinicaltrialsonline.comAAcadia Pharmaceuticals publishes interim LOTUS study data in journalSeptember 12, 2025 | msn.comReal World Data from LOTUS Study Evaluating Long-term Efficacy and Tolerability Outcomes of DAYBUE® (trofinetide) in Patients with Rett Syndrome Published in Developmental ...September 12, 2025 | finance.yahoo.comPTT to sell stake in Taiwan pharmaceuticals firmJuly 25, 2025 | msn.comSamarsh Capital, Vyom Partners, Blue Lotus Lead INR 50 Cr Investment in Sai ParenteralsJuly 8, 2025 | msn.comGeely’s Lotus says ‘no plans’ to close any factoryJuly 2, 2025 | msn.comLotus Pharmaceutical Co Ltd (1795) - Investing.com UKJune 26, 2025 | uk.investing.comLotus Therapeutics Appoints Leslie Felix as Chief Growth OfficerJune 4, 2025 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesSpaceX Gets the Attention, But These 4 Stocks Could Get the ReturnsBy Bridget Bennett | May 25, 2026Rocket Lab Is Down 24% From Its 52-Week High—Pullback or Problem?By Ryan Hasson | June 4, 20262 Software Stocks Turning AI Fears Into Fundamental GainsBy Dan Schmidt | May 21, 2026MongoDB Is the Latest SaaS Apocalypse Victim to Say "Not Today"By Sam Quirke | June 3, 2026Allstate’s Comeback Is Turning Into a Profit MachineBy Peter Frank | June 8, 2026LTUS, GRML, ATHE, and ADXS Company DescriptionsAyala Pharmaceuticals NASDAQ:ADXS$0.60 0.00 (0.00%) As of 06/10/2026Ayala Pharmaceuticals, Inc., a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. The company's lead candidates under development include AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia. Ayala Pharmaceuticals, Inc. is based in Wilmington, Delaware.Alterity Therapeutics NASDAQ:ATHE$4.20 -201.30 (-97.96%) As of 09:31 AM Eastern This is a fair market value price provided by Massive. Learn more.Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434 that is in Phase I clinical trial for the treatment of Parkinson's disease. It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; ATH434-202 that is in Phase II clinical trial to treat multiple system atrophy advance; and PBT2 that has completed Phase 2a clinical trial to treat Alzheimer's disease. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is headquartered in Melbourne, Australia.Greenland Mines Ltd. Common Stock NASDAQ:GRML$0.30 -0.01 (-1.64%) As of 09:04 AM EasternGreenland Mines Ltd develops essential medicines for the treatment of chronic diseases - cancer, cardiovascular, and neurodegenerative disorders. The Company operates as a single reporting segment focused on developing essential medicines for these chronic diseases. The Company has acquired two licensed platforms: a generic drug portfolio and a biosimilar biologics platform that uses biologic therapies to treat cancer, and proprietary patented technologies involving melanocortin receptor-binding molecules and a gene therapy platform that introduces a therapeutic protein called Klotho inside the body to treat neurodegenerative diseases.Lotus Pharmaceuticals OTCMKTS:LTUS$0.0036 0.00 (0.00%) As of 06/10/2026Lotus Pharmaceuticals, Inc. does not have significant operations. Previously, it was engaged in the development, manufacture, and sale of pharmaceuticals in the People's Republic of China. The company is based in Nashville, Tennessee. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Spotify's "North Star" Outlook Was Music to Investors Ears DraftKings Hits the Jackpot With Super App Pivot Cracker Barrel Surges 23% as Earnings Beat Signals Turnaround Progress Microsoft Just Gave Investors 3 Dates They Can't Afford to Ignore SpaceX IPO Fears Are Overblown, But the AI Bet Is Real The Biggest Opportunity From SpaceX’s IPO May Surprise You NVIDIA’s Outlook Gains Momentum: Stock Price to Follow Chewy’s Growth Engine Is Stronger Than the Market Thinks Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
